

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Werner Seeger et al.

Serial. No. : 10/583,785 Examiner: TBA

Filed : June 19, 2006 Group Art Unit: 4411

Title : NOVEL CHIMERIC PLASMINOGEN ACTIVATORS
AND THEIR PHARMACEUTICAL USE

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

The applicants respectfully submit herewith an Information Disclosure Statement (IDS), and an Information Disclosure Citation List, and a copy of each document listed therein, pursuant to 37 C.F.R. §§ 1.97 and 1.98. The Examiner is requested to consider the enclosed documents, make them of record, and indicate his or her consideration of the documents by initialing the enclosed Citation List adjacent the citation of each document. Please return a copy of the initialed Citation form to the applicant's undersigned Attorney.

This IDS is being filed under 37 CFR 1.97(b). Thus, no fee is due.

() This IDS is being filed within three months of the filing date of a national application other than a continued prosecution application (CPA).

() This IDS is being filed within three months of the date of entry of the national stage in an international application.


(X) This IDS is being filed before the mailing date of a first Office Action on the merits.

() This IDS is being filed before the mailing of a first Office Action after the filing of a request for continued examination (RCE).


The Commissioner is hereby authorized to charge any deficiency, or to credit any overpayment, to the undersigned attorney's Deposit Account No. 02-4270.

Respectfully submitted,

Dated: March 8, 2007


James P. Demers. No. 34,320
BROWN RAYSMAN MILLSTEIN
FELDER & STEINER LLP
900 Third Avenue
New York, New York 10022
(212) 895-2000

I hereby certify that this paper is being deposited this date with the U.S. Postal Service as
First Class Mail addressed to: Commissioner for Patents, Washington, D.C. 20231


James P. Demers

3/8/07
Date



Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449-RIO

(Use as many sheets as necessary)

Complete if Known

Application Number	10/583,785
Filing Date	06/19/2006
First Named Inventor	Seeger
Art Unit	4411
Examiner Name	tba
Attorney Docket Number	7927-01

Sheet	1	of	2
-------	---	----	---

[illegible][illegible]

Examiner
Signature

Date	
Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/583,785
				Filing Date	06/19/2006
				First Named Inventor	Seeger
				Art Unit	4411
				Examiner Name	tba
Sheet	2	of	2	Attorney Docket Number	7927-01

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		A. GUNTHER et al., "Surfactant alteration and replacement in acute respiratory distress syndrome", <i>Respir. Res.</i> 2001, 2 :353-364	
		S. IDELL et al., "Local Abnormalities in coagulation and Fibrinolytic Pathways Predispose to Alveolar Fibrin Deposition in the Adult Respiratory Distress Syndrome", <i>J. Clin. Invest.</i> 1989, 84 :695-705	
		A. GUNTHER et al., "Alveolar Fibrin Formation Caused by Enhanced Procoagulant and Depressed Fibrinolytic Capacities in Severe Pneumonia", <i>Am. J. Respir. Crit. Care Med.</i> 2000, 161 :454-462	
		K. Yamada, "Adhesive Recognition Sequences", <i>J. Biol. Chem.</i> 1991, 266 :12809-12812	
		R. SCHERMULY et al., "Conebulization of surfactant and urokinase restores gas exchange in perfused lungs ...", <i>Am. J. Physiol. Lung Cell. Mol. Physiol.</i> 2001, 280 :L792-L800	
		P. MARKART et al., "Fibrinolysis-inhibitory capacity of clot-embedded surfactant is enhanced by SP-B and SP-C", <i>Am. J. Physiol. Lung Cell. Mol. Physiol.</i> 2003, 284 :L69-L76	
		A. GUNTHER et al., "Cleavage of Surfactant-Incorporating Fibrin by Different Fibrinolytic Agents", <i>Am. J. Respir. Cell Mol. Biol.</i> 1999, 21 :738-745	
		C. RUPPERT et al., "Chemical Coupling of a Monoclonal Antisurfactant Protein-B Antibody to Human Urokinase for Targeting Surfactant-Incorporating Alveolar Fibrin", <i>Bioconjugate Chem.</i> 2002, 13 :804-811	
		C. RUPPERT et al., "Chemical Crosslinking of Urokinase to Pulmonary Surfactant protein B for Targeting Alveolar Fibrin", <i>Thromb. Haemost.</i> 2003, 89 :53-64	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.